FY22 results largely pre-date the strategic decision to focus active R&D exclusively on the exosome platform, primarily as a drug delivery modality. ReNeuron is switching staff and financial resources onto this exciting, but early-stage platform, although recognition of its value still needs to be established. ReNeuron has seven research collaborations in exosomes with more under discussion and has shown that these can deliver a potent growth factor to the brain in an animal model. New explorato ....
07 Jul 2022
ReNeuron Group Prelims
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ReNeuron Group Prelims
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
07 Jul 2022 -
Author:
Robin Davison | John Savin -
Pages:
6
FY22 results largely pre-date the strategic decision to focus active R&D exclusively on the exosome platform, primarily as a drug delivery modality. ReNeuron is switching staff and financial resources onto this exciting, but early-stage platform, although recognition of its value still needs to be established. ReNeuron has seven research collaborations in exosomes with more under discussion and has shown that these can deliver a potent growth factor to the brain in an animal model. New explorato ....